Nexodal (Naloxone Hydrochloride)

Naloxone Hydrochloride, the active ingredient in Nexodal, is an opioid antagonist presented as an injection solution for intramuscular and intravenous use. It reverses opioid‑induced respiratory depression and is used in emergency treatment of opioid overdose. Nexodal is manufactured for the EU market and is supplied in a sterile vial for rapid administration in acute settings.

GNH USA supplies Nexodal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Naloxone Hydrochloride is an opioid antagonist used to counteract opioid toxicity.

- Opioid overdose: rapid reversal of life‑threatening respiratory depression. - Opioid‑induced respiratory depression: restores normal breathing in patients receiving opioid analgesia. - Post‑operative opioid overdose: provides emergency reversal when overdose occurs after surgery.

Adverse reactions may occur following administration of Nexodal.

Common Side Effects: - Nausea - Vomiting - Sweating - Increased heart rate

Serious or Rare Side Effects: - Severe hypertension - Cardiac arrhythmia - Pulmonary edema - Anaphylactic reaction

When using Nexodal, several safety considerations are recommended.

- Airway assessment: ensure the patient’s airway is protected before administration. - Vital sign monitoring: continuously observe respiratory rate, blood pressure, and heart rate after dosing. - Indication verification: use only when opioid overdose or opioid‑induced respiratory depression is suspected. - Hypersensitivity check: avoid in patients with known allergy to naloxone or excipients. - Chronic opioid users: be aware that rapid reversal may precipitate acute withdrawal symptoms. - Store at ambient temperature: keep below 25 °C in the original container, protect from light and moisture.

Naloxone may interact with other medications, requiring careful management.

Major Interactions (Avoid): - Concurrent potent opioid agonists can diminish reversal effectiveness. - Mixed agonist‑antagonist opioids (e.g., buprenorphine) may precipitate severe withdrawal. - Co‑administration with vasopressors may mask hypotension.

Moderate Interactions (Monitor Closely): - Sedative agents such as benzodiazepines may require additional respiratory support. - Monoamine oxidase inhibitors can increase the risk of hypertension. - Cardiac glycosides may need monitoring for arrhythmias after rapid opioid reversal.